Azacitidine and Venetoclax in Previously Untreated Acute Myeloid ...

The incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received azacitidine alone.

In previously untreated patients who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission ...

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid ...

Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added ...

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid ...

In more than 400 older patients with AML who could not receive myeloablative therapy, the incidence of composite complete remission was higher (66.4% vs.

Combination of Azacitidine and Venetoclax in Previously Untreated

In VIALE-A clinical trial, previously untreated patients with acute myeloid leukaemia (AML) who were ineligible for intensive chemotherapy ...

Cost-effectiveness of azacitidine and venetoclax in unfit patients with ...

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Kishan K. Patel,.

Cost-effectiveness of azacitidine and venetoclax in unfit patients with ...

... previously untreated acute myeloid leukemia (AML). However, the cost-effectiveness of azacitidine-venetoclax in this clinical setting is unknown ...

Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in ...

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7): 617-629. 10.1056/NEJMoa2012971. CAS ...

Venetoclax and Azacitidine in Chinese patients with untreated acute ...

Acute Myeloid Leukemia (AML) patients are often found ineligible for aggressive standard chemotherapy in clinic because of old age and poor ...

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid ...

The Cochrane Library · Scolaris Search Portlet Scolaris Search Portlet · Scolaris Language Selector Scolaris Language Selector · Scolaris Content Language ...

Cost-effectiveness of azacitidine and venetoclax in unfit patients with ...

HEALTH SERVICES AND OUTCOMES. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid ...

Azacitidine and venetoclax in previously untreated acute myeloid ...

CONCLUSIONS In previously untreated patients who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of ...

Azacitidine plus Venetoclax for Acute Myeloid Leukemia

However, azacitidine monotherapy has been associated with a remission rate ≤30% and survival of <1 year in untreated AML patients ≥65 years of ...

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid ...

... Treatment with the BCL2 inhibitor venetoclax in combination with a hypomethylating agent (azacitidine or decitabine) in elderly and unfit ...

Venetoclax combined with decitabine or azacitidine in treatment ...

, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a ...

Older Patients With Previously Untreated AML May Benefit from ...

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629. doi:10.1056/NEJMoa2012971. Share ...

Safety and preliminary efficacy of venetoclax with decitabine or ...

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid ...

Medline ® Abstracts for References 26,31 of 'Acute myeloid leukemia

26: PubMed |; TI: Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. AU: DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, ...

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid ...

In more than 400 older patients with AML who could not receive myeloablative therapy, the incidence of composite complete remission was higher (66.4% vs.

Venetoclax with decitabine or azacitidine in previously untreated ...

Venetoclax with decitabine or azacitidine in previously untreated TP53mut acute myeloid leukemia. Authors: Kyle Zacholski, Ian Michael ...